logo-loader
Genedrive PLC

Genedrive welcomes BGF as a cornerstone investor as it proposes to raise £6mln

The proposed financing will "help the group drive towards demonstrable revenue growth and to advance the group's portfolio of additional tests, which if successful, are expected to increase shareholder value and enhance the strategic value of the group's diagnostics technologies"

Ten pound note
BGF has made a non-binding commitment to invest a further £1mln in new equity via the placing that is conditional, among other things, on the company raising an additional £2.5mln in new equity

Rapid diagnostics specialist genedrive PLC (LON:GDR) has raised £5.6mln, net of expenses, through a successful placing of shares and the issue of convertible loan notes.

The company said it raised gross proceeds of £3.5mln via a conditional placing of 15,217,391 shares at 23p each  – last night’s closing mid-market price – with new and existing investors. In afternoon trading, genedrive shares held steady at the 23p level.

READ: genedrive shares push higher as the rapid diagnostics specialist gears up for important year

genedrive raised a further £2.5mln through the issue of convertible loan notes to small and medium-cap backer, BGF.

The loan notes, which carry a coupon of 7%, mature on June 30, 2025 and will be convertible into genedrive shares at 28.75p a pop.

The company has also announced a proposal to raise up to a further £500,000 by way of a broker option to allow existing and other investors to participate in the fund-raising at the 23p-a-share placing price, which will be open until 6 December 2018.

The net proceeds will fund the working capital needs of the company in relation to the launch of the Genedrive HCV-ID Kit for Hepatitis C diagnosis and support projects to enhance the gross margin for this assay.

The money will also fund the company's assay development programmes in antibiotic-induced hearing loss (AIHL) and tuberculosis (mTB) and the continued development of the Genedrive system.

"The HCV market is significant with many millions of people affected by the disease in low and middle-income countries but low diagnosis rates. We have the first-to-market point-of-need molecular test, a strong commercial platform and a clear strategy to deliver revenue growth. A test for antibiotic-induced hearing loss, a first product aimed at non-LMIC markets, and the re-launch mTB provide further potential to benefit from the capabilities of our Genedrive diagnostics platform,” said David Budd, the chief executive officer of genedrive.

"Securing BGF as a cornerstone investor and the fundraising we have announced today will put us in a strong position to deliver on these opportunities," he added.

In a separate announcement, the company revealed it had £3.5mln in cash at the end of June, down from £5.1mln the year before, after posting a loss before tax of £7.8mln in the year to the end of June, versus a loss the year before of £7.6mln.

Revenue declined to £1.94mln from £2.61mln.

“Progress during the year has been positive,” Budd said, with the company accomplishing many of the objectives it had set itself at the start of the financial year.

 - Adds placing completion details, share price --  

Quick facts: Genedrive PLC

Price: £0.17

Market: AIM
Market Cap: £5.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genedrive PLC optimistic on the long-term opportunity for its HCV test

Genedrive PLC (LON:GDR) CEO David Budd tells Proactive London's Andrew Scott he remains confident the World Health Organisation will pre-qualify its HCV ID hepatitis C test in the near term despite some delays to the clinical trial. He adds that the development of an antibiotic-induced...

on 12/7/19

3 min read